Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M G Fury

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
FEBS Letters|March 3, 1997
In vitro interaction of U2 snRNA with cytoplasmic 6S protein complexesM G Fury, J Andersen
Experimental Cell Research|October 10, 1996
U6 snRNA maturation and stabilityM G Fury, G W Zieve
Experimental Cell Research|January 7, 1998
Multiple protein: protein interactions between the snRNP common core proteinsM G Fury, W Zhang, I Christodoulopoulos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 5, 2018
A phase II study of temsirolimus added to low-dose weekly carboplatin and paclitaxel for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)L A Dunn, M G Fury, H Xiao, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 30, 2017
A phase II study of temsirolimus added to low-dose weekly carboplatin and paclitaxel for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)L A Dunn, M G Fury, H Xiao, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 28, 2016
A phase II study of axitinib (AG-013736) in patients with incurable adenoid cystic carcinomaA L Ho, L Dunn, E J Sherman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 6, 2014
Phase I study of weekly nab-paclitaxel + weekly cetuximab + intensity-modulated radiation therapy (IMRT) in patients with stage III-IVB head and neck squamous cell carcinoma (HNSCC)M G Fury, E J Sherman, S S Rao, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 10, 2023
Final analysis of phase II results with cemiplimab in metastatic basal cell carcinoma after hedgehog pathway inhibitorsK D Lewis, K Peris, A Sekulic, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
FEBS Letters|March 3, 1997
In vitro interaction of U2 snRNA with cytoplasmic 6S protein complexesM G Fury, J Andersen
Experimental Cell Research|October 10, 1996
U6 snRNA maturation and stabilityM G Fury, G W Zieve
Experimental Cell Research|January 7, 1998
Multiple protein: protein interactions between the snRNP common core proteinsM G Fury, W Zhang, I Christodoulopoulos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 5, 2018
A phase II study of temsirolimus added to low-dose weekly carboplatin and paclitaxel for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)L A Dunn, M G Fury, H Xiao, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 30, 2017
A phase II study of temsirolimus added to low-dose weekly carboplatin and paclitaxel for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)L A Dunn, M G Fury, H Xiao, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 28, 2016
A phase II study of axitinib (AG-013736) in patients with incurable adenoid cystic carcinomaA L Ho, L Dunn, E J Sherman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 6, 2014
Phase I study of weekly nab-paclitaxel + weekly cetuximab + intensity-modulated radiation therapy (IMRT) in patients with stage III-IVB head and neck squamous cell carcinoma (HNSCC)M G Fury, E J Sherman, S S Rao, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 10, 2023
Final analysis of phase II results with cemiplimab in metastatic basal cell carcinoma after hedgehog pathway inhibitorsK D Lewis, K Peris, A Sekulic, et al.
Pageof 1